연구성과로 돌아가기
2024 연구성과별 연구자 정보 (757 / 2344)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| Elucidating Singlet-Fission-Born Multiexciton Dynamics via Molecular Engineering: A Dilution Principle Extended to Quintet Triplet Pair | Teo, Hao Ting | Teo, HT | 2 | Natl Univ Singapore, Dept Chem, Singapore 117543, Singapore | chmcc@nus.edu.sg;dongho@yonsei.ac.kr; | |||||
| Elucidating Singlet-Fission-Born Multiexciton Dynamics via Molecular Engineering: A Dilution Principle Extended to Quintet Triplet Pair | Hong, Yongseok | Hong, Y | 3 | Yonsei Univ, Dept Chem, Spect Lab Funct p Elect Syst, Seoul 03722, South Korea | 0000-0002-8095-3148 | Hong, Yongseok | chmcc@nus.edu.sg;dongho@yonsei.ac.kr; | |||
| Elucidating Singlet-Fission-Born Multiexciton Dynamics via Molecular Engineering: A Dilution Principle Extended to Quintet Triplet Pair | Cha, Hyojung | Cha, H | 4 | Kyungpook Natl Univ, Dept Hydrogen & Renewable Energy, Daegu 41566, South Korea | chmcc@nus.edu.sg;dongho@yonsei.ac.kr; | |||||
| Elucidating Singlet-Fission-Born Multiexciton Dynamics via Molecular Engineering: A Dilution Principle Extended to Quintet Triplet Pair | Kim, Woojae | Kim, W | 5 | Yonsei Univ, Dept Chem, Spect Lab Funct p Elect Syst, Seoul 03722, South Korea | JYQ-4232-2024 | Kim, Woojae | 0000-0001-8638-8744 | Kim, Woojae | chmcc@nus.edu.sg;dongho@yonsei.ac.kr; | |
| Elucidating Singlet-Fission-Born Multiexciton Dynamics via Molecular Engineering: A Dilution Principle Extended to Quintet Triplet Pair | Chi, Chunyan | Chi, CY | 6 | 교신저자 | Natl Univ Singapore, Dept Chem, Singapore 117543, Singapore | H-8684-2013 | Y., Chun | 0000-0003-4677-3546 | Chi, Chunyan | chmcc@nus.edu.sg;dongho@yonsei.ac.kr; |
| Elucidating Singlet-Fission-Born Multiexciton Dynamics via Molecular Engineering: A Dilution Principle Extended to Quintet Triplet Pair | Kim, Dongho | Kim, D | 7 | 교신저자 | Yonsei Univ, Dept Chem, Spect Lab Funct p Elect Syst, Seoul 03722, South Korea | KIK-0073-2024 | , dongho | chmcc@nus.edu.sg;dongho@yonsei.ac.kr; | ||
| Embedding-based Two-Stage Entity Alignment for Cross-Lingual Knowledge Graphs * | Sun, Yuxiang | Sun, YX | 1 | Kyungpook Natl Univ, Software Technol Res Ctr, Daegu 41566, South Korea | HPH-6656-2023 | Sun, Yuxiang | syx921120@gmail.com;yongju@knu.ac.kr; | |||
| Embedding-based Two-Stage Entity Alignment for Cross-Lingual Knowledge Graphs * | Lee, Yongju | Lee, YJ | 2 | 교신저자 | Kyungpook Natl Univ, Sch Comp Sci & Engn, Daegu 41566, South Korea | GYE-1759-2022 | Lee, Yong-Ju | syx921120@gmail.com;yongju@knu.ac.kr; | ||
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Lencioni, Riccardo | Lencioni, R | 1 | Univ Pisa, Sch Med, Dept Diagnost & Intervent Radiol, Pisa, Italy | ||||||
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Kudo, Masatoshi | Kudo, M | 2 | Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka, Japan | AAA-9744-2019 | Kudo, Masatoshi | ||||
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Erinjeri, Joseph | Erinjeri, J | 3 | Mem Sloan Kettering Canc Ctr, Intervent Radiol Serv, New York, NY USA | ||||||
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Qin, Shukui | Qin, SK | 4 | Nanjing Univ Chinese Med, Jinling Hosp, Canc Ctr, Nanjing, Peoples R China | ||||||
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Ren, Zhenggang | Ren, ZG | 5 | Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China | ||||||
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Chan, Stephen | Chan, S | 6 | Chinese Univ Hong Kong, Sir Yue Kong Pao Ctr Canc, State Key Lab Translat Oncol, Dept Clin Oncol, Hong Kong, Peoples R China | ||||||
| EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | Arai, Yasuaki | Arai, Y | 7 | Natl Canc Ctr, Dept Diagnost Radiol, Chuo Ku, Tokyo, Japan |
페이지 이동: